SYDNEY, April 10, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), a leading developer of a new class of synthetic anti-infectives, today announced a ...

Its popular open-source project is growing quickly, with users including The Philadelphia Inquirer and government entities in Brazil and Australia Recce was created as an open-source project in ...

This approval will allow up to 20 additional patients to access RECCE® 327 Topical Gel (R327G) under the existing open-label study protocol. R327G has attracted strong interest from investigators ...

In a strong validation of the company’s clinical pipeline, Recce Pharmaceuticals has secured $5 million via a share placement with a private, Australian-based investor. The company has also ...

Recce secures A$5M from private investor and launches A$10.8M entitlement offer to fund Phase III topical clinical trials The smart money in medicine: the silent pandemic Recce Pharmaceuticals ...

Recce Pharmaceuticals is commercializing a novel synthetic broad-spectrum antibiotic designed to overcome antimicrobial resistance. Its lead compound, RECCE 327, is one of the first entirely new ...

Recce Pharmaceuticals receives Human Research Ethics Committee approval to expand its phase II clinical trial following positive results. Follows recently released positive Phase II clinical trial ...

Additional proceeds from the Entitlement Offer will be allocated to other programs currently in development by the Company. Recce will look at alternative funding solutions to ensure the full quantum ...